NCI Definition: A cystic adenocarcinoma that arises from the pancreas. It includes the acinar cell and serous cystadenocarcinoma subtypes. 
There is 1 clinical trial for pancreatic cystadenocarcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains pancreatic cystadenocarcinoma as an inclusion criterion, 1 is phase 2 (1 open).
Ipilimumab and nivolumab are the most common interventions in pancreatic cystadenocarcinoma clinical trials.
Significant Genes in Pancreatic Cystadenocarcinoma
CD274 is an inclusion eligibility criterion in 1 clinical trial for pancreatic cystadenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and pancreatic cystadenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.